GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » 3-Year Revenue Growth Rate

Wakamoto Pharmaceutical Co (TSE:4512) 3-Year Revenue Growth Rate : -4.50% (As of Mar. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co 3-Year Revenue Growth Rate?

Wakamoto Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was 円62.01.

During the past 12 months, Wakamoto Pharmaceutical Co's average Revenue per Share Growth Rate was -10.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -4.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -6.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Wakamoto Pharmaceutical Co was 4.50% per year. The lowest was -7.90% per year. And the median was -0.60% per year.


Competitive Comparison of Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate falls into.



Wakamoto Pharmaceutical Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Wakamoto Pharmaceutical Co  (TSE:4512) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Wakamoto Pharmaceutical Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Wakamoto Pharmaceutical Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Wakamoto Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines